Lupin’s new wholly owned subsidiary receives letter of incorporation from MCA

The subsidiary was incorporated on March 8, according to a regulatory filing.

The board of directors had previously approved the incorporation in a meeting held on February 11, 2025.

The company informed about the development through the stock exchanges after the market hours.

Lupin share performance

On Tuesday, shares of Lupin settled at ₹2,036.05 apiece, rising 2.22% on the National Stock Exchange (NSE).

The stock has fallen 3.03% since Monday, March 10 but gained 6.83% on a month-to-date basis. It has declined steeply by 13.63% since the beginning of the year.

The pharmaceutical scrip had touched its 52-week high of ₹2,402.90 apiece on January 2, 2025 and one-year low of ₹1,493.30 per share on June 4, 2024.

Lupin Ltd has a total market capitalisation of ₹92,954.02 crore as of March 18, 2025, on the NSE and had a trading volume of 5.45 lakh on the same day.

Third quarter results

Lupin’s consolidated net profit increased 38.8% year-on-year (YoY) from ₹859.9 crore in the third quarter of the 2024-25 fiscal year (Q3 FY25), compared to ₹618.7 crore in the corresponding period last year.

Its sales for the December quarter stood at ₹5,618.6 crore, jumping 10.6% from ₹5,079.9 crore in the third quarter of the 2023-24 financial year (Q3 FY24).

Its earnings before interest, taxes, depreciation, and amortisation (EBITDA) was at ₹1,409.6 crore in Q3FY25, up 32.1% against ₹1,067.3 crore in Q3FY24.